Safety and Efficacy of Camrelizumab (Anti-PD-1 Antibody) in Recurrent HCC After Liver Transplantation

NCT ID: NCT04564313

Last Updated: 2022-05-03

Basic Information

• Recruitment Status: UNKNOWN
• Clinical Phase: PHASE1
• Total Enrollment: 20 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2020-09-21
• Study Completion Date: 2023-07-31

Brief Summary

This is a prospective clinical study to investigate the safety and efficacy of anti-PD-1 immunotherapy (Camrelizumab) in patients with recurrent hepatocellular carcinoma (HCC) after liver transplantation. All of the enrolled patients have a background of liver transplantation for HCC. Due to the tumor recurrence, patients are not suitable for curative surgical resection, and targeted therapy provides poor therapeutic effect, leading to tumor progression or intolerance. Before immunotherapy, the PD-L1 expression was confirmed negative in the graft liver by immunohistochemistry, and patients continued targeted therapy as part of a combined antitumor regimen. In addition, the immunosuppression schedule is also reduced to a low level.

Conditions

Hepatocellular Carcinoma; Liver Transplantation

Study Design

• Allocation Method: NA
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

Camrelizumab treatment

Camrelizumab (SHR-1210), 200mg, I.V., Q3W

Group Type: EXPERIMENTAL

Camrelizumab treatment

Intervention Type: DRUG

Camrelizumab (SHR-1210), 200mg, I.V., Q3W

Interventions

Camrelizumab treatment

Camrelizumab (SHR-1210), 200mg, I.V., Q3W

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

1. Age 18-65 years old, male or female;

2. Pathologically confirmed hepatocellular carcinoma after liver transplantation;

3. Tumor recurrence or metastasis is confirmed by CT and/or MRI examination, and neither intrahepatic recurrence nor extrahepatic metastasis is suitable for surgical resection;

4. At least one measurable recurrent or metastatic tumor lesion;

5. Tumor progression (mRECIST) or intolerance to treatment was assessed at least 1 month after oral administration of sorafenib or lenvatinib;

6. The expected survival time is more than 3 months;

7. Child-Pugh grade A or B (≤7 points);

8. Other vital organs' function: The absolute count of neutrophils ≥1.5×10E9/L; Platelet ≥50×10E9/L; Hemoglobin ≥9g/dL; Serum albumin ≥2.8g/dL; Thyroid stimulating hormone (TSH) ≤1 times ULN (If TSH is abnormal, T3 and T4 levels should be examined at the same time. Then, if both T3 and T4 levels are normal, patient could be enrolled); Bilirubin ≤1.5 times ULN; ALT and AST ≤3 times ULN; Serum creatinine ≤1.5 times ULN;

9. ECOG score 0-2 points;

10. Patients have sufficient understanding and voluntarily sign the informed consent, and are willing and able to comply with the visit, treatment plan, laboratory examination and other requirements of the study schedule.

Exclusion Criteria

1. Positive PD-L1 expression in liver biopsy by immunohistochemistry (either liver parenchyma or non-parenchymal cells);

2. Be Allergic to Camrelizumab;

3. ≥ Grade II myocardial ischemia or myocardial infarction;

4. With hypertension that can't be controlled to normal level with medication (SBP >140mmHg, DBP >90mmHg);

5. With abnormal coagulation function (PT>16s, APTT>43s, TT>21s, Fbg<2g/L), and with a history of gastrointestinal bleeding within 6 months;

6. With high risk of bleeding or is receiving thrombolysis or anticoagulant therapy;

7. With autoimmune diseases including systemic lupus erythematosus, rheumatoid arthritis, psoriasis, etc;

8. The primary liver disease for liver transplantation was autoimmune hepatitis, primary biliary cirrhosis, or primary sclerosing cholangitis;

9. With pulmonary diseases such as interstitial pneumonia and poor lung function;

10. Participating in clinical trials of other experimental drugs within four weeks;

11. With infections requiring systemic treatment;

12. With positive infection of human immunodeficiency virus (HIV);

13. Special groups that not recommended in the instructions of Camrelizumab: with moderate or severe insufficiency of liver and renal function;

14. With MDM2/4 amplification, EGFR mutation, or JAK mutation by NGS sequencing;

15. With other factors that may influence the safety or compliance;

16. During the treatment of acute rejection or within 1 month after treatment;

17. Poor compliance.

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 65 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Third Affiliated Hospital, Sun Yat-Sen University

OTHER

Sponsor Role: lead

Responsible Party

Wang Guoying

M.D.

Responsibility Role: PRINCIPAL_INVESTIGATOR

Locations

Third Affiliated Hospital, Sun Yat-sen University

Guangzhou, Guangdong, China

Site Status: RECRUITING

Countries

China

Central Contacts

Guoying Wang, M.D.

Role: CONTACT

wanggy3@126.com

+86-13632407313

Facility Contacts

Wang Guoying, M.D.

Role: primary

wanggy3@126.com

086-13632407313

Other Identifiers

[2020]-02-061-01

Identifier Type: -

Identifier Source: org_study_id